The UHS Heart & Vascular Institute recently celebrated a significant milestone with the completion of their 1,000th TAVR (Transcatheter Aortic Valve Replacement) procedure. This achievement is more ...
The Lee Health Heart Institute recently hit a significant milestone—the team has performed more than 2,000 transcatheter aortic valve replacement (TAVR) procedures! The expert team of interventional ...
CHICAGO — Five years after treatment, patients with severe aortic stenosis had comparable rates of all-cause mortality or disabling stroke, whether they received transcatheter aortic valve replacement ...
WASHINGTON, DC — New European registry data on transcatheter aortic-valve replacement (TAVR) in patients at lower surgical risk than those studied in the pivotal randomized trials offers the ...
SHREVEPORT, La. - Transcatheter aortic valve replacement (TAVR), is a minimally invasive procedure used to treat aortic stenosis, a condition where the heart's aortic valve narrows and restricts blood ...
Of the two heart valve surgeries Janice Smith has had at OhioHealth Mansfield Hospital, the second was much easier for her. "I had a good experience both times," the 86-year-old said. "It's just that ...
Cardiothoracic Surgeon Geoffrey R. Cousins, MD, FACS, left, and Interventional Cardiologist Jason Schott, DO, mark the 100th transcatheter aortic valve replacement procedure performed at Memorial ...
CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...
High-risk surgical patients with severe aortic stenosis who underwent a transcatheter aortic valve replacement experienced higher one-year survival rates than patients who underwent traditional ...
GRAND RAPIDS, Mich. — There's a procedure offered at Corewell that's extending lives. It's called transcatheter aortic valve replacement, or TAVR. Before this procedure, the options for patients were ...
Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results